Impacts on GRP78 and LOX-1 expression by TM treatment in hepatic L02 cells.

<p>A: Expression levels of GRP78 and LOX-1 in hepatic L02 cells exposed to different concentrations (0.1, 0.5, 1, 1.5, or 2 μg/mL) of TM. Cells were harvested at 24 h after exposure to TM, and the expression levels of GRP78, LOX-1, and β-actin were examined by western blot. B: Impact of the time course of TM treatment on expression. The cells were exposed to TM (1 μg/mL) for 6, 12, or 24 h. Expression levels of GRP78, LOX-1, and β-actin were examined by western blot. C: Immunostaining of GRP78 (red) and LOX-1 (green) in L02 cells before (control) and after TM treatment (1 μg/mL, 24 h). Nuclei were counterstained with DAPI (blue). These data are representative of three independent experiments. *<i>P</i> < 0.05; **<i>P</i> < 0.01, compared with the control. TM: tunicamycin.